2.9678
price up icon1.64%   0.0478
after-market Handel nachbörslich: 3.10 0.1322 +4.45%
loading
Schlusskurs vom Vortag:
$2.92
Offen:
$2.9
24-Stunden-Volumen:
60,364
Relative Volume:
0.41
Marktkapitalisierung:
$2.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-15.52M
KGV:
-0.1597
EPS:
-18.58
Netto-Cashflow:
$-16.61M
1W Leistung:
-7.40%
1M Leistung:
+9.92%
6M Leistung:
-77.71%
1J Leistung:
-91.25%
1-Tages-Spanne:
Value
$2.80
$3.1096
1-Wochen-Bereich:
Value
$2.76
$3.3223
52-Wochen-Spanne:
Value
$2.36
$60.80

Revelation Biosciences Inc Stock (REVB) Company Profile

Name
Firmenname
Revelation Biosciences Inc
Name
Telefon
650-800-3717
Name
Adresse
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Name
Mitarbeiter
9
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
REVB's Discussions on Twitter

Vergleichen Sie REVB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
REVB
Revelation Biosciences Inc
2.9678 2.90M 0 -15.52M -16.61M -18.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
503.50 126.09B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
568.91 64.01B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
629.51 36.63B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
257.19 30.64B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.77 27.24B 3.81B -644.79M -669.77M -6.24

Revelation Biosciences Inc Aktie (REVB) Neueste Nachrichten

pulisher
11:41 AM

REVB: New Target Market Announced - Research Tree

11:41 AM
pulisher
09:00 AM

Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients - Yahoo Finance

09:00 AM
pulisher
Apr 10, 2025

Why Revelation Biosciences Inc. (REVB) Went Down On Thursday? - Insider Monkey

Apr 10, 2025
pulisher
Mar 21, 2025

Revelation Biosciences (REVB) to Release Earnings on Friday - Defense World

Mar 21, 2025
pulisher
Mar 17, 2025

REVB stock touches 52-week low at $2.71 amid sharp annual decline - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

REVB stock touches 52-week low at $2.71 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 17, 2025
pulisher
Mar 17, 2025

Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

Revelation Biosciences: Gemini priming attenuates inflammatory response in PBMCs - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

Gemini Priming Attenuates Inflammation In Human Peripheral Blood Mononuclear Cells - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells - Business Wire

Mar 17, 2025
pulisher
Mar 13, 2025

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference - Business Wire

Mar 13, 2025
pulisher
Mar 10, 2025

What is Roth Capital’s Estimate for REVB FY2029 Earnings? - Defense World

Mar 10, 2025
pulisher
Mar 07, 2025

REVB: 2025 Is the Year for Measurable Progress - Research Tree

Mar 07, 2025
pulisher
Mar 06, 2025

Revelation Biosciences Inc. (REVB) reports earnings - Quartz

Mar 06, 2025
pulisher
Mar 06, 2025

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024 - WICZ

Mar 06, 2025
pulisher
Feb 26, 2025

Revelation Biosciences stock hits 52-week low at $3.26 By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 26, 2025

Revelation Biosciences stock hits 52-week low at $3.26 - Investing.com

Feb 26, 2025
pulisher
Feb 26, 2025

Revelation Biosciences Doses First Patient In Prime Phase 1B Clinical Study Of Gemini In CKD Patients - Marketscreener.com

Feb 26, 2025
pulisher
Feb 26, 2025

Revelation doses first patient in PRIME Phase 1b clinical study - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients - Business Wire

Feb 26, 2025
pulisher
Feb 26, 2025

Artificial Intelligence (AI) News Live Feed - StockTitan

Feb 26, 2025
pulisher
Feb 24, 2025

Revelation Biosciences gets continued listing approval from Nasdaq - MSN

Feb 24, 2025
pulisher
Feb 24, 2025

Revelation Biosciences Says Regained Compliance With Nasdaq Minimum Bid Price Requirement - marketscreener.com

Feb 24, 2025
pulisher
Feb 24, 2025

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval - Business Wire

Feb 24, 2025
pulisher
Feb 24, 2025

Can This Biotech's New Kidney Disease Trial Transform CKD Treatment? Key Details - Stock Titan

Feb 24, 2025
pulisher
Feb 13, 2025

Larchmont broker accused of years-long insider trading scheme - Westfair Communications

Feb 13, 2025
pulisher
Feb 11, 2025

Allergic Rhinitis Market Expected to rise, 2034 | Regeneron, - openPR

Feb 11, 2025
pulisher
Feb 03, 2025

Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews

Feb 03, 2025
pulisher
Jan 30, 2025

Neumora Therapeutics, Rain Oncology, and Carmell Corporation: Stock Volatility Highlights Major Market Moves - HPBL

Jan 30, 2025
pulisher
Jan 30, 2025

Allergic Rhinitis Market to Show Remarkable Growth Trends from - openPR

Jan 30, 2025
pulisher
Jan 30, 2025

Revelation Biosciences stock hits 52-week low at $0.28 - MSN

Jan 30, 2025
pulisher
Jan 29, 2025

REVB Start 1B Trial and Announces Split - MSN

Jan 29, 2025
pulisher
Jan 29, 2025

REVB: Phase 1b Begins and Nasdaq Compliance Regained - Research Tree

Jan 29, 2025
pulisher
Jan 28, 2025

Stock market news: MiNK Therapeutics -93.51%, Revelation Biosciences -93.45% among biggest losers during mid day trading - Business Upturn

Jan 28, 2025
pulisher
Jan 28, 2025

Stock market news: Vincerx Pharma plunged by 95.86% while MiNK Therapeutics was down by 94.26% during mid day trading - Business Upturn

Jan 28, 2025
pulisher
Jan 28, 2025

Stock market today: Revelation Biosciences -93.16%, MiNK Therapeutics -91.40% among biggest losers in early trading - Business Upturn

Jan 28, 2025
pulisher
Jan 28, 2025

Stock market today: Vincerx Pharma declined by 95.75% whereas Revelation Biosciences - Business Upturn

Jan 28, 2025
pulisher
Jan 28, 2025

Revelation Biosciences Inc (REVB) Has Strong Growth Prospects Through 2025 - Marketing Sentinel

Jan 28, 2025
pulisher
Jan 27, 2025

Anthem man charged with insider trading - Foothills Focus

Jan 27, 2025
pulisher
Jan 24, 2025

Revelation Biosciences stock hits 52-week low at $0.28 By Investing.com - Investing.com Canada

Jan 24, 2025
pulisher
Jan 24, 2025

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025 - BioSpace

Jan 24, 2025
pulisher
Jan 24, 2025

Revelation Biosciences to effect 1-for-16 reverse stock split to regain Nasdaq compliance - MSN

Jan 24, 2025
pulisher
Jan 21, 2025

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients - Marketscreener.com

Jan 21, 2025
pulisher
Jan 21, 2025

Revelation Bio Launches Phase 1b Trial of Gemini for Advanced Chronic Kidney Disease Treatment - Stock Titan

Jan 21, 2025
pulisher
Jan 20, 2025

Florida Trader Among 4 Arrested for 7-Year-Long Insider Trading Scheme - NewsBreak

Jan 20, 2025
pulisher
Jan 19, 2025

Revelation Biosciences (REVB) Price Target Increased by 242.79% to 40.04 - MSN

Jan 19, 2025

Finanzdaten der Revelation Biosciences Inc-Aktie (REVB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.79
price up icon 0.78%
$71.40
price up icon 2.20%
$32.71
price up icon 0.52%
$23.62
price down icon 2.03%
$104.00
price up icon 0.00%
biotechnology ONC
$249.77
price up icon 0.12%
Kapitalisierung:     |  Volumen (24h):